Latest / Decera Clinical Education Oncology Podcast
New Evidence With BTK Inhibitor Therapy in CLL and MCL From EHA 2022
In this episode, Othman Al-Sawaf, MD, and Lydia Scarfò, MD, discuss key trials presented at EHA 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of:
GAIA/CLL13: phase III trial of time-limited venetoclax + obinutuzumab ± ibrutinib vs chemoimmunotherapy as first-line therapy for CLL
FLAIR: randomized, adaptive-design phase III trial with data reported from ibrutinib + venetoclax and ibrutinib arm; includes measurable residual disease–defined therapy duration
BRUIN: phase I/II study of pirtobrutinib…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.